A deal for Becton Dickinson’s biosciences and diagnostic solutions unit puts Waters Corp. in a greater position to compete ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

Waters Corporation (WAT) stock downgraded at Wells Fargo based on execution risks related to its $17.5B M&A deal with a unit of Becton Dickinson (BDX). Read more here;.

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of ...

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.

Recent developments illustrate dynamic shifts in the healthcare sector. Trump's spending bill is anticipated to challenge ...

Medical analysis equipment maker Waters is combining with a unit of Becton Dickinson in a complex spin-merge. At a discount ...

Waters Corporation is merging with BD’s Biosciences and Diagnostic Solutions business in a $17.5 billion deal to expand its capabilities in life sciences and diagnostics.

Bank of New York Mellon logged higher-than-expected earnings and revenue in the second quarter, helped by its fast-growing net interest income. Dave & Buster's Entertainment named Tarun Lal as chief ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.